8-K: DIH Reports FY25 Losses, Nasdaq Listing Under Review

DIH Holding US, Inc. announced its fiscal year 2025 financial results, reporting a revenue decrease and negative operating cash flow, alongside significant capital raising activities and a pending Nasdaq listing decision.

Summary

• Fiscal year 2025 revenue decreased by 2.5% to $62.9 million, with device revenue down 2.8% to $49.7 million and service revenue up 8.4% to $12.0 million.
• Gross profit for the fiscal year increased by 8.2% to $32.2 million, driven by a decrease in cost of goods due to product mix changes and a lesser inventory reserve.
• Operating loss for fiscal year 2025 widened to $7.0 million from $2.6 million in the prior year, and net loss increased to $8.7 million from $8.4 million.
• The company reported negative operating cash flow of $4.1 million for the fiscal year, a significant shift from positive operating cash flow of $5.2 million in the prior year.
• Cash and cash equivalents stood at $1.9 million as of March 31, 2025, down from $3.2 million in the prior year.
• Fourth quarter 2025 revenue decreased by 34.7% to $12.6 million, primarily due to lower sales volume in EMEA impacted by wartime import restrictions in Eastern Europe.
• Impairment losses totaling $2.1 million were recognized in Q4 FY2025 due to the discontinuation of the SafeGait product ($0.6 million) and cessation of HocoNet platform software development ($1.5 million).
• Subsequent to year-end, DIH engaged in significant financing activities, including a $2.2 million senior secured convertible debenture private placement and an equity line of credit for up to $22 million.
• A 1-for-25 reverse stock split was approved by stockholders on September 25, 2025, and became effective on October 20, 2025, reducing outstanding shares from approximately 52.3 million to 2.1 million.
• The company is awaiting the results of a Nasdaq hearing panel regarding its listing status, which was held on October 16, 2025.

Sentiment

Score: 3

Explanation: The company reported declining revenue, negative operating cash flow, and widening losses. Significant impairment charges and a pending Nasdaq listing review add to the negative sentiment. While capital raises provide some liquidity, they come with substantial dilution and ongoing debt obligations. The reverse stock split is a measure to maintain listing, often indicative of underlying stock price weakness.

Positives

• Service revenue increased by 8.4% to $12.0 million for the fiscal year ended March 31, 2025.
• Gross profit for the fiscal year increased by 8.2% to $32.2 million, driven by a decrease in cost of goods.
• Net loss per share decreased to $(6.07) in fiscal year 2025 from $(8.00) in fiscal year 2024, despite a higher net loss, due to an increase in weighted-average shares outstanding.
• Selling, general and administrative expenses decreased by 8.7% in the fourth quarter of fiscal year 2025, partly due to $0.7 million in cost reductions from efficiency initiatives.
• Successful capital raising efforts post-year-end, including a $2.2 million senior secured convertible debenture and an equity line of credit for up to $22 million, provide liquidity.

Negatives

• Fiscal year 2025 revenue decreased by 2.5% to $62.9 million, primarily due to a change in product mix with lower average sales prices.
• Device revenue decreased by 2.8% to $49.7 million for the fiscal year.
• Negative operating cash flow of $4.1 million for the fiscal year ended March 31, 2025, a significant deterioration from positive operating cash flow in the prior year.
• Operating loss widened to $7.0 million in fiscal year 2025 from $2.6 million in the prior year.
• Net loss increased to $8.7 million in fiscal year 2025 from $8.4 million in the prior year.
• Cash and cash equivalents decreased to $1.9 million at March 31, 2025, from $3.2 million in the prior year.
• Fourth quarter 2025 revenue decreased significantly by 34.7% to $12.6 million, largely due to lower sales volume in EMEA impacted by wartime import restrictions.
• Impairment losses totaling $2.1 million were recognized in Q4 FY2025 for discontinued products (SafeGait) and software development (HocoNet platform).
• Selling, general and administrative expense increased by 16.3% to $30.0 million for the fiscal year, driven by higher personnel expenses and a $1.1 million impairment of related party receivable.
• The company is awaiting the results of a Nasdaq hearing panel regarding its listing status, indicating potential delisting risk.
• The reverse stock split was implemented to support Nasdaq listing compliance, often a sign of a struggling stock price.

Risks

• Nasdaq Listing Status: The company is awaiting the results of a Nasdaq hearing panel regarding its listing status, held on October 16, 2025, which could result in delisting.
• Operational Cash Flow: Negative operating cash flow of $4.1 million for the fiscal year indicates a reliance on financing activities to sustain operations.
• Revenue Decline: Overall revenue decreased, and Q4 revenue saw a significant 34.7% decline, partly due to external factors like wartime import restrictions in EMEA, which could persist.
• Product Development Impairments: Discontinuation of SafeGait product and HocoNet platform development resulted in $2.1 million in impairment losses, indicating challenges in product commercialization and R&D effectiveness.
• Foreign Currency Fluctuations: Changes in foreign currency exchange rates had an unfavorable impact on net sales, particularly from Euro valuations.
• Reliance on Financing: Subsequent events show a heavy reliance on convertible debentures and equity lines of credit, which can dilute existing shareholders and add debt.
• Shareholder Dilution: The issuance of 1,540,277 shares for debt settlement, 8,888,888 warrants, and up to 10,458,031 shares under the equity line of credit, along with 2,500,000 shares as an upfront commitment fee, indicates significant potential for future shareholder dilution.
• Debt Obligations: Monthly redemptions of $171 thousand for the new debentures starting October 1, 2025, create ongoing cash demands.
• Market Conditions: General economic, political, and business conditions, as well as the ability to achieve projected revenue, are cited as risks in forward-looking statements.

Future Outlook

Management is committed to driving innovation, delivering value, and maintaining operational discipline. The company is focused on positioning DIH for long-term success while awaiting the results of the NASDAQ hearing panel regarding its listing status.

Management Comments

• DIH remains committed to driving innovation and delivering value for patients and healthcare providers.
• During this year, we made meaningful progress across our key strategic initiatives while maintaining our focus on operational discipline.
• As we look forward to the results of the NASDAQ hearing panel regarding our listing status held on October 16, 2025, our team is committed to positioning DIH for long-term success.

Industry Context

DIH operates in the specialized and growing market of robotic devices for physical rehabilitation, a sector focused on improving patient outcomes through advanced technology. The company's strategy involves consolidating a fragmented, manual-labor-driven industry. The reported revenue decline, particularly in EMEA due to geopolitical conflicts, highlights the vulnerability of global supply chains and sales networks to external macroeconomic and political events, a common challenge for international medical device companies. The significant capital raising activities and reverse stock split indicate efforts to stabilize financial health and maintain market listing, which are common strategies for smaller, growth-oriented companies facing liquidity and compliance pressures in competitive markets.

Comparison to Industry Standards

• The negative operating cash flow of $4.1 million and widening net loss of $8.7 million suggest DIH is underperforming compared to established, profitable medical device companies like Stryker or Intuitive Surgical, which typically demonstrate strong positive cash flows and consistent profitability.
• The significant revenue decline in Q4, particularly due to geopolitical factors in EMEA, indicates a higher exposure to regional instability compared to more diversified global players in the rehabilitation technology space.
• The need for a reverse stock split to maintain Nasdaq listing compliance is a red flag, often seen in companies struggling with sustained low stock prices, unlike industry leaders that maintain robust market valuations.
• The reliance on convertible debentures and an equity line of credit for financing, coupled with significant potential for shareholder dilution, is a common characteristic of early-stage or financially distressed companies, rather than mature, self-sustaining industry benchmarks.
• The impairment losses on SafeGait and HocoNet platforms suggest challenges in R&D commercialization and product lifecycle management, which could be a concern when compared to companies with a strong track record of successful product launches and innovation.

Corporate Governance

Related Party Transactions

• Impairment of related party receivable of $1.1 million in fiscal year 2025 due to a settlement of related party balances.
• Due from related party decreased from $5,688k in 2024 to $3,468k in 2025.
• Due to related party decreased from $10,192k in 2024 to $7,919k in 2025.
• Notes payable related party decreased from $11,457k in 2024 to $8,601k in 2025.
• Amendment to Securities Purchase Agreement with Five Narrow Lane (a related party) on May 29, 2025, for debt settlement and future redemption terms.
• Equity line of credit agreement with Five Narrow Lane, L.P. (the investor) on October 15, 2025.

Stakeholder Impact

• Shareholders: Face significant potential dilution from new debentures, warrants, and the equity line of credit. The reverse stock split aims to maintain Nasdaq listing, but the underlying financial performance is weak, potentially leading to further share price volatility.
• Creditors (Debenture Holders): The new senior secured convertible debentures provide security and a clear redemption schedule, but also include conversion options that could lead to equity ownership. The waiver of default by Five Narrow Lane indicates a willingness to work with the company.
• Employees: Personnel expenses increased due to compensation, merit increases, and headcount additions, suggesting some positive impact on employees, but the discontinuation of products (SafeGait) and platforms (HocoNet) could imply job insecurity in those specific areas.
• Customers: The discontinuation of products like SafeGait and HocoNet platform might impact customers relying on those specific solutions, while the focus on expanding service department in established regions could benefit others.
• Suppliers: No direct impact mentioned, but declining revenue and negative cash flow could put pressure on payment terms or future orders.

Next Steps

• Await results of the NASDAQ hearing panel regarding listing status.
• File the Annual Report on Form 10-K.
• Deliver a substantially complete draft Form 10-Q for the quarter ended June 30, 2025.
• Appoint one additional independent director to secure the final tranche of debenture funding.
• Seek shareholder approval under Nasdaq rules for additional share issuances related to debentures and warrants.
• Include proxy proposals authorizing a reverse stock split (already approved and effected) and amending certain debentures to align conversion prices.
• Continue monthly redemptions of $171 thousand for the new debentures starting October 1, 2025.
• Manage the equity line of credit for potential future capital needs.

Key Dates

Recommendation

The company exhibits significant financial distress with declining revenue, widening losses, and negative operating cash flow. The substantial Q4 revenue drop, partly due to geopolitical risks, highlights operational vulnerabilities. While recent capital raises provide short-term liquidity, they come with considerable shareholder dilution and ongoing debt obligations. The reverse stock split, implemented to maintain Nasdaq listing, is a strong indicator of underlying stock price weakness and investor concern. The pending Nasdaq listing decision adds further uncertainty and risk of delisting. Given these factors, the stock presents a high-risk profile with limited clear upside catalysts, making a 'sell' recommendation appropriate for risk-averse investors.

Keywords

Robotic Rehabilitation, Physical Therapy Devices, Medical Devices, Healthcare Technology, SEC Filing, Financial Results, Nasdaq Listing, Reverse Stock Split, Convertible Debentures, Equity Line of Credit, DIH Holding US Inc., DHAI, Operating Loss, Cash Flow, Impairment Loss